Long-term Benefit of MPA in Liver Transplantation

Sun Yat-sen University

Status

Enrolling

Conditions

Immunosuppressant Adverse Reaction

Liver Transplant Rejection

Treatments

Drug: None MPA

Drug: enteric-coated mycophenolate (MPAs)

Study type

Observational

Funder types

Other

Identifiers

NCT05707520

[2022]02-146-01

Details and patient eligibility

About

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

Enrollment

500 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who underwent their first liver transplantation between January 1, 2016 and February 28, 2021;
Recipient's survival time≥ 1 year;
Age 18~65 years old;
Patients with complete data and no loss to follow-up.

Exclusion criteria

use of other types of anti-metabolic immunosuppressants;
Second liver transplantation for various reasons within 1 year after the first transplantation;
Patients with serious underlying diseases, including heart disease, infection and renal insufficiency, combined with other malignant tumors.